Acute Inflammation – Friday Pop Quiz 11/17/2023
Increased expression of which of the following is most associated with the patient’s condition? A. Interferon-gamma B. Interleukin-2 C. Interleukin-13 D. Transforming growth factor-beta E. Tumor necrosis factor-alpha To find out the correct answer and read the explanation, click here.    Brought to you by our brand partner    …
Cicatricial Alopecias: Practical Pearls for Challenging Diagnoses
cicatricial alopeciasAt ODAC 2023, we had the opportunity to learn about cicatricial alopecias from renowned dermatologist and hair expert Dr. Amy McMichael, Professor of Dermatology at Wake Forest University School of Medicine. First, we considered a framework to check for cicatricial alopecias. This is particularly important because if we can identify cicatricial alopecia, we can make sure we are treating the rig …
cicatricial alopecias
Topical Ruxolitinib Therapeutic Cheat Sheet
RuxolitinibRuxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT …
Ruxolitinib
Vitiligo Medical Treatment Advances | Expert Insights
vitiligoNext Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium interviewed Dr. Amit Pandya, staff dermatologist with Palo Alto Foundation Medical Group and adjunct professor in the department of dermatology at the University of Texas Southwestern Medical Center. Dr. Pandya says this is the most exciting time for him as a dermatologist with new vitiligo medications on the market an …
vitiligo